HEINEKEN NV
Heineken N.V. reports 2024 full year results
Heineken N.V. reports 2024 full year results
Heineken N.V. reports 2024 full year results
Amsterdam, 12 February 2025 – Heineken N.V. (HEINEKEN) [(EURONEXT: HEIA; OTCQX: HEINY)] announces:
Solid results with broad-based growth and profit expansion in 2024
Key Highlights |
- Revenue €35,955 million
- Net revenue (beia) 5.0% organic growth, per hectolitre 3.5%
- Beer volume 1.6% organic growth; Heineken® volume up 8.8%
- Operating profit €3,517 million; operating profit (beia) 8.3% organic growth
- Operating profit (beia) margin 15.1%, up 40 bps
- Net profit €978 million; net profit (beia) 7.3% organic growth
- Diluted EPS (beia) €4.89
- Free Operating Cash Flow €3,058 million
- HEINEKEN to launch two-year €1.5 billion share buyback programme
- Full year 2025 outlook: 4% to 8% operating profit (beia) organic growth
CEO Statement |
Dolf van den Brink, Chairman of the Executive Board / CEO, commented:
"We delivered solid results with broad-based growth and profit expansion in 2024. Beer volume grew organically by 1.6%, and net revenue (beia) was up 5.0% with strong operating profit (beia) growth of 8.3%. Notably, our beer volume expanded in all four regions, across both developed and emerging markets.
Our EverGreen strategy continued to shape operations. Premium volume grew 5%, led globally by Heineken®, which was up 9%. Mainstream beer volume rose 2%, spearheaded by the leading brands in our largest markets, including Amstel in Brazil, Cruzcampo in the UK, and Kingfisher in India. The beyond beer segment grew 4%, led by Desperados globally and Savanna cider in Southern Africa. Heineken® 0.0 grew 10%, reinforcing our global leadership in non-alcoholic beer.
Gross savings exceeded €0.6 billion, supporting a 40 bps operating margin (beia) expansion. Marketing and selling investment increased by €0.3 billion, a double-digit organic increase, and we stepped up funding behind our digital and technology initiatives. Capital productivity focus helped deliver a strong free operating cash flow, exceeding €3 billion.
Looking ahead, we are well-positioned to further increase our investment in marketing and selling and behind our EverGreen priorities in 2025. We expect to grow operating profit (beia) organically in the range of 4% to 8%."
Enquiries |
Media | Investors | |
Christiaan Prins | Tristan van Strien | |
Director of Global Communication | Global Director of Investor Relations | |
Marlie Paauw | Lennart Scholtus / Chris Steyn | |
Corporate Communications Lead | Investor Relations Manager / Senior Analyst | |
E-mail: pressoffice@heineken.com | E-mail: investors@heineken.com | |
Tel: +31-20-5239355 | Tel: +31-20-5239590 |
Conference Call Details |
HEINEKEN will host an analyst and investor video webcast about its 2024 FY results today, 12 February, at 14:00 CET/ 13:00 GMT/ 08.00 EST. The live video webcast will be accessible via the company’s website: https://www.theheinekencompany.com/investors/results-reports-webcasts-and-presentations.
An audio replay service will also be made available after the webcast at the above web address. Analysts and investors can dial-in using the following telephone numbers:
United Kingdom (local): +44 20 3936 2999 |
Netherlands (local): +31 85 888 7233 |
United States: +1 646 787 9445 |
All other locations: +44 20 3936 2999 |
For the full list of dial in numbers, please refer to the following link: Global Dial-In Numbers |
Participation password for all countries: 962302 |
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ONWARD Medical NV28.4.2025 08:30:00 CEST | Press release
ONWARD Medical Announces Release of 2024 Annual Report
Purespring Therapeutics28.4.2025 08:00:00 CEST | Press release
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
FreeMove Alliance28.4.2025 08:00:00 CEST | Press release
FreeMove Alliance and du cooperate to better serve Multinationals in the United Arab Emirates
LIfT BioSciences28.4.2025 08:00:00 CEST | Press release
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland
Fingerprint Cards AB28.4.2025 08:00:00 CEST | Press release
Mantra Softech extends licence for FPC iris technology to expand into new markets
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom